Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale of the Company, a business combination, merger or other strategic transaction, or an orderly wind-down of operations.